Skip to content

Clinical Evaluation of Darvi Raskriya kawal in reducing the symptoms of redness of pharyngeal tonsil, throat pain ,size, post nasal discharge in the treatment of Gilayu (Acute Tonsillitis)

Randomised Controlled Clinical Trial to Determine the Efficacy of Darvi raskriya kawal in the management of Gilayu w.s.r. to A. Tonsillitis - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/03/105205
Enrollment
80
Registered
2026-03-02
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J039- Acute tonsillitis, unspecified

Interventions

None listed

Sponsors

Dr Pratiksha Premdas Rathod
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patient between age 18-50 yrs 2.Patients with clinical symptoms (redness of pharyngeal tonsil, swelling, throat pain from 4 to 6 days but not more than 2 weeks. 3.selections of Patients will be irrespective of their sex, religion, Socioeconomic Status 4. No history of allergies to Betadine or herbal ingredients. 5. Is willing to provide informed consent and adhere to the treatment. 6.Tonsilar Hypertropy, throat pain during swallowing as cardinal symptoms must be present in patient

Exclusion criteria

Exclusion criteria: 1. Patient who had peritonsilar abcess, pus pocket, quinsy, laryngeal oedema, para pharyngeal abscess, septicemia, high grade fever are excluded from the Study 2. Patients Suffering from any other systemic disorders like DM, HTN, diseases of oral-Cavity. 3. Allergic history to herbal or Betadine formulations 4. Pregnant, lactating mothers. 5.patient who will be any other medication for the same symptoms will be not taken for the study.

Design outcomes

Primary

MeasureTime frame
Reduction in sign and symptoms redness of pharyngeal tonsil, throat pain,size,post nasal dischargeTimepoint: Total duration of treatment- 2 weeks Assessment on 1st,2nd week Post treatment follow up-3rd week

Secondary

MeasureTime frame
NILTimepoint: NIL

Countries

India

Contacts

Public ContactDr Amol Walzade

SST Ayurved Mahavidyalaya,Sangamner

dramolwalzade@gmail.com9823553070

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026